The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

BZ Group
  • 5.0 (1)
  • Life Sciences
  • Updated Daily

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

  1. 2h ago

    Week in Review | GSK Kills Camlipixant: The P2X3 Cough Bet Just Went to Zero

    GSK wrote off most of a $2 billion bet as camlipixantbecomes the third P2X3 antagonist to fail in chronic cough. Plus Lilly's $2.8B AtaiBeckley deal and July's IPO wave, Novartis Fabhalta's full approval in IgAN, Celcuity's Revtorpyk, Merck's oral PCSK9 pill and sac-TMT lung-cancerdata, the Jasper–Kira merger, and the Sanofi Sarclisa FDA decision ahead. Visit us at thepharmacloseout.com.

  2. 1d ago

    Daily Roundup | GSK Kills Camlipixant: The $2B Bellus Bet Unravels

    GSK shelved camlipixant after mixed Phase 3 data — the third P2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabhalta's full FDA approval in IgA nephropathy, Lilly's $2.8B AtaiBeckley psychedelics buyout, a Merck ADC lung cancer readout, and a Pfizer downgrade. Visit us at thepharmacloseout.com.

  3. 3d ago

    Daily Roundup | Merck's Sac-TMT Beats Chemo in Lung Cancer — Keytruda's Cliff Answer

    Merck's sac-TMT beat chemotherapy in first-line PD-L1-negative lung cancer — the emerging answer to Keytruda's patent cliff. Plus: Europe approves Novo Nordisk's oral Wegovy ahead of Eli Lilly, Sanofi sues Pfizer and Moderna over mRNA patents, Bora and Insilico Medicine ink a $2.5B AI alliance, the FDA resumes publishing complete response letters, Q32 Bio surges on alopecia areata data, and Veradermics posts a Phase 2 win in female pattern hair loss. Visit us at thepharmacloseout.com.

  4. 4d ago

    Daily Roundup | Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target

    Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diranersen tau data at AAIC, the NextCure–Avere oral IL-23 merger, and Roche scrapping two Ionis Huntington's programs. Visit us at thepharmacloseout.com.

  5. 6d ago

    Daily Roundup | GSK to File Jemperli in Rectal Cancer After Phase 2 Win

    GSK will file Jemperli with the FDA for dMMR rectal cancer after a Phase 2 win, extending its PD-1 franchise into curative-intent oncology. Plus Q32 Bio's bempikibart hits its alopecia areata goal, the FDA finalizes psychedelics guidance ahead of a Compass Pathways COMP360 decision, LEQEMBI clears a subcutaneous at-home dose for Eisai and Biogen, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, and Biogen's tau drug diranersen takes the spotlight at AAIC. Visit us at thepharmacloseout.com.

  6. 6d ago

    Week in Review | AstraZeneca's Wainua Stumbles: The Clinic Pushed Back on Pharma's Deal Boom

    AstraZeneca's Wainua missed in cardiomyopathy — one of three clinical setbacks in five days even as pharma dealmaking stayed red-hot with Vertex's ~$10B Crinetics buy and GSK's biggest oncology bet in a decade. We break down what the Wainua miss means for the ATTR cardiomyopathy race, Bausch + Lomb's BL1107 glaucoma flop, the third Hengrui/Elevar liver-cancer rejection, Corcept's misread insider sale and late-2026 Cushing's catalyst for relacorilant, plus the week ahead: Q32 Bio's bempikibart in alopecia areata, Celcuity's gedatolisib FDA decision in breast cancer, Novartis's pelacarsen, and Lilly's muted Foundayo launch. Visit us at thepharmacloseout.com.

  7. Jul 11

    Daily Roundup | GSK Ends Alector Neuroscience Bet: What the $2.2B Unwind Signals

    GSK walked away from its $2.2 billion Alector alliance, ending its neuroscience re-entry as clinical setbacks piled up. Plus: the FDA resumes releasing rejection letters with fourteen new CRLs, Hengrui and Elevar's PD-1 liver cancer combo is rejected a third time, Sanofi's subcutaneous Sarclisa wins approval, Pfizer/Astellas and Merck expand Padcev-Keytruda in muscle-invasive bladder cancer, Vera Therapeutics scores an IgA nephropathy nod against Otsuka, AstraZeneca and Ionis miss a Phase 3 heart trial, Apnimed files to IPO amid its sleep apnea review, and Moderna sinks in a broad biotech selloff. Visit us at thepharmacloseout.com.

  8. Jul 10

    Daily Roundup | Wainua Fails Pivotal ATTR-CM Trial; Ionis Sinks 20%

    AstraZeneca and Ionis's Wainua missed its Phase 3 ATTR-CM endpoint — Ionis fell ~20% while BridgeBio surged ~17%. We break down the CARDIO-TTRansform failure and what it means for Alnylam's Amvuttra and BridgeBio's Attruby, plus Roche scrapping tominersen in Huntington's, GSK exiting its Alector pact, Ipsen's Dysport dual Phase 3 migraine wins, Vera Therapeutics' IgA nephropathy approval versus Otsuka, NICE rejecting Amgen's Lumakras, and Sino Biopharm's China deals with AstraZeneca and GSK. Visit us at thepharmacloseout.com.

See All (104)

About

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

Information

You Might Also Like